BioAtla (BCAB) Projected to Post Quarterly Earnings on Thursday

BioAtla (NASDAQ:BCAB) will likely be releasing its earnings data after the market closes on Thursday, March 27th. Analysts expect BioAtla to post earnings of ($0.40) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

BioAtla Stock Down 0.8 %

BCAB opened at $0.37 on Wednesday. BioAtla has a 52 week low of $0.24 and a 52 week high of $4.02. The business’s 50 day moving average is $0.41 and its two-hundred day moving average is $1.15. The firm has a market cap of $17.74 million, a price-to-earnings ratio of -0.22 and a beta of 1.19.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.